Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovisâ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovisâ regulatory and commercialization paths. Clovis believes this approach to precision medicineâto deliver the right drug to the right patient at the right timeârepresents the future of cancer therapy. Source
No articles found.
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, de...
Entasis is a clinical-stage biopharmaceutical c...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
ACS Global, Inc. engages in the collection, processing, and long-term storage of s...
ACS Global, Inc. engages in the collection, pro...
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, an...
HTG Molecular Diagnostics, Inc. ("HTG") is a pr...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
Join the National Investor Network and get the latest information with your interests in mind.